Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs

Summary

The physician-scientist helped advance landmark tumor-agnostic therapies that target the genetic drivers of cancer. NEW YORK, Oct. 22, 2026 — NYU Langone Health today announced the appointment of Vivek Subbia...